Differential expression of filamin B splice variants in giant cell tumor cells

Tsui,Joseph Chi-Ching; Lau,Carol Po-Ying; Cheung,Alex Chun; Wong,Kwok-Chuen; Huang,Lin; Tsui,Stephen Kwok-Wing; Kumta,Shekhar Madhukar

doi:10.3892/or.2016.5197

Differential expression of filamin B splice variants in giant cell tumor cells

Authors:
- Joseph Chi-Ching Tsui
- Carol Po-Ying Lau
- Alex Chun Cheung
- Kwok-Chuen Wong
- Lin Huang
- Stephen Kwok-Wing Tsui
- Shekhar Madhukar Kumta
View Affiliations

Affiliations: Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, P.R. China, School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, P.R. China, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, P.R. China
Published online on: October 24, 2016 https://doi.org/10.3892/or.2016.5197
Pages: 3181-3187
Copyright: © Tsui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Giant cell tumor of bone (GCT) is the most commonly reported non-malignant bone tumor in Hong Kong. This kind of tumor usually affects people aged 20-40 years. Also, it is well known for recurrence locally, especially when the tumor cannot be removed completely. Filamins are actin-binding proteins which contain three family members, filamin A, B and C. They are the products of three different genes, FLNA, FLNB and FLNC, which can generate various transcript variants in different cell types. In this study, we focused on the effects of FLNBv2 and FLNBv4 toward GCT cells. The only difference between FLNBv2 and FLNBv4 is that FLNBv4 does not contain hinge 1 region. We found that the relative abundance of FLNBv4 varies among different GCT cell lines while the expression level of FLNBv4 in normal osteoblasts was only marginally detectable. In the functional aspect, overexpression of FLNBv4 led to upregulation of RANKL, OCN, OPG and RUNX2, which are closely related to GCT cell survival and differentiation. Moreover, FLNBv4 can have a negative effect on cell viability of GCT cells when compare with FLNBv2. In conclusion, splicing variants of FLNB are differentially expressed in GCT cells and may play a role in the proliferation and differentiation of tumor cells.

View Figures

View References

1	Yip KM, Leung PC and Kumta SM: Giant cell tumor of bone. Clin Orthop Relat Res. 323:60–64. 1996. View Article : Google Scholar
2	Leung KH, Lam AY, Ho KW and Shek TW: Giant cell tumor of the humeral head treated by denosumab: Implication to shoulder surgeons. Int J Shoulder Surg. 9:135–138. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zheng MH, Robbins P, Xu J, Huang L, Wood D and Papadimitriou J: The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol. 16:297–307. 2001.PubMed/NCBI
4	Sobti A, Agrawal P, Agarwala S and Agarwal M: Giant cell tumor of bone - An overview. Arch Bone Jt Surg. 4:2–9. 2016.PubMed/NCBI
5	James IE, Walsh S, Dodds RA and Gowen M: Production and characterization of osteoclast-selective monoclonal antibodies that distinguish between multinucleated cells derived from different human tissues. J Histochem Cytochem. 39:905–914. 1991. View Article : Google Scholar : PubMed/NCBI
6	Huang L, Teng XY, Cheng YY, Lee KM and Kumta SM: Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone. 34:393–401. 2004. View Article : Google Scholar : PubMed/NCBI
7	Razinia Z, Mäkelä T, Ylänne J and Calderwood DA: Filamins in mechanosensing and signaling. Annu Rev Biophys. 41:227–246. 2012. View Article : Google Scholar : PubMed/NCBI
8	Jeon GW, Lee MN, Jung JM, Hong SY, Kim YN, Sin JB and Ki CS: Identification of a de novo heterozygous missense FLNB mutation in lethal atelosteogenesis type I by exome sequencing. Ann Lab Med. 34:134–138. 2014. View Article : Google Scholar : PubMed/NCBI
9	Nakamura F, Stossel TP and Hartwig JH: The filamins: Organizers of cell structure and function. Cell Adhes Migr. 5:160–169. 2011. View Article : Google Scholar
10	Popowicz GM, Schleicher M, Noegel AA and Holak TA: Filamins: Promiscuous organizers of the cytoskeleton. Trends Biochem Sci. 31:411–419. 2006. View Article : Google Scholar : PubMed/NCBI
11	Stossel TP: Filamins and the potential of complexity. Cell Cycle. 9:14632010. View Article : Google Scholar : PubMed/NCBI
12	Gorlin JB, Yamin R, Egan S, Stewart M, Stossel TP, Kwiatkowski DJ and Hartwig JH: Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): A molecular leaf spring. J Cell Biol. 111:1089–1105. 1990. View Article : Google Scholar : PubMed/NCBI
13	Pudas R, Kiema TR, Butler PJ, Stewart M and Ylänne J: Structural basis for vertebrate filamin dimerization. Structure. 13:111–119. 2005. View Article : Google Scholar : PubMed/NCBI
14	Sawyer GM and Sutherland-Smith AJ: Crystal structure of the filamin N-terminal region reveals a hinge between the actin binding and first repeat domains. J Mol Biol. 424:240–247. 2012. View Article : Google Scholar : PubMed/NCBI
15	Nakamura F, Osborn TM, Hartemink CA, Hartwig JH and Stossel TP: Structural basis of filamin A functions. J Cell Biol. 179:1011–1025. 2007. View Article : Google Scholar : PubMed/NCBI
16	Xu W, Xie Z, Chung DW and Davie EW: A novel human actin-binding protein homologue that binds to platelet glycoprotein Ibalpha. Blood. 92:1268–1276. 1998.PubMed/NCBI
17	Dalkilic I, Schienda J, Thompson TG and Kunkel LM: Loss of FilaminC (FLNc) results in severe defects in myogenesis and myotube structure. Mol Cell Biol. 26:6522–6534. 2006. View Article : Google Scholar : PubMed/NCBI
18	van der Flier A, Kuikman I, Kramer D, Geerts D, Kreft M, Takafuta T, Shapiro SS and Sonnenberg A: Different splice variants of filamin-B affect myogenesis, subcellular distribution, and determine binding to integrin [beta] subunits. J Cell Biol. 156:361–376. 2002. View Article : Google Scholar : PubMed/NCBI
19	Giancotti FG and Ruoslahti E: Integrin signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
20	Lau CP, Ng PK, Li MS, Tsui SK, Huang L and Kumta SM: p63 regulates cell proliferation and cell cycle progression associated genes in stromal cells of giant cell tumor of the bone. Int J Oncol. 42:437–443. 2013.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Wu PF, Tang JY and Li KH: RANK pathway in giant cell tumor of bone: Pathogenesis and therapeutic aspects. Tumour Biol. 36:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
23	Wang T, Yin H, Wang J, Li Z, Wei H, Liu Z, Wu Z, Yan W, Liu T, Song D, et al: MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone. Oncotarget. 6:18980–18996. 2015. View Article : Google Scholar : PubMed/NCBI
24	Lau CP, Huang L, Tsui SK, Ng PK, Leung PY and Kumta SM: Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone. J Orthop Res. 29:403–413. 2011. View Article : Google Scholar : PubMed/NCBI
25	Huang L, Cheng YY, Chow LT, Zheng MH and Kumta SM: Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases. J Clin Pathol. 55:877–878. 2002. View Article : Google Scholar : PubMed/NCBI
26	Dong SS, Liu XG, Chen Y, Guo Y, Wang L, Zhao J, Xiong DH, Xu XH, Recker RR and Deng HW: Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in Caucasians. Calcif Tissue Int. 85:104–112. 2009. View Article : Google Scholar : PubMed/NCBI
27	Huang Q, Jiang Z, Meng T, Yin H, Wang J, Wan W, Cheng M, Yan W, Liu T, Song D, et al: MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone. Biochem Biophys Res Commun. 453:160–165. 2014. View Article : Google Scholar : PubMed/NCBI
28	Neve A, Corrado A and Cantatore FP: Osteocalcin: Skeletal and extra-skeletal effects. J Cell Physiol. 228:1149–1153. 2013. View Article : Google Scholar : PubMed/NCBI
29	Huang L, Xu J, Wood DJ and Zheng MH: Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol. 156:761–767. 2000. View Article : Google Scholar : PubMed/NCBI